研发新冠疫苗的医疗研究人员和各大公司都在搜寻治疗新冠病毒的捷径,并在这一期间获得了来自于人工智能超级计算机的协助。
在疫情爆发伊始,IBM面向全球数百所大学、公司以及梅约诊所和克利夫兰诊所这类医疗机构部署了Watson人工智能。IBM Watson Health业务总经理保尔·罗玛在周二《财富》杂志举办的线上健康头脑风暴大会上称,他们“都在这个组装起来的超级计算机上进行试验,并获取发现。”
例如,梅约诊所正在研究采用恢复期血浆疗法(也就是采用从愈后新冠病毒患者身体中采集的抗体)来治疗新冠病毒,同时也在IBM的帮助下探索现有疗法治疗其他疾病的潜在疗效。
梅约诊所的总裁兼首席执行官吉安里克·法鲁吉亚在虚拟会议上说:“我们知道不能坐等疫苗的出现。我们必须携手IBM和其他合作伙伴,打造这个生态系统,并回收该系统中的旧药品。”
例如,法鲁吉亚提到了吉利德的试验药物瑞德西韦,这是第一个获美国食品与药品管理局新冠病毒治疗紧急授权的疗法。多年来,该药一直在围绕治疗埃博拉等其他病毒进行实验。法鲁吉亚称:“瑞德西韦并不是老药,但也不是新药。”
罗玛指出,IBM Watson的优势在于超级计算机加速研究过程的能力。他说:“以往在标准传统的计算环境中需要数周来建模和运行的事情基本上可以在几分钟之内完成。你可以在一天的时间内完成此前需要数月才能完成的建模和工作。”
通过与众多开发疫苗的机构合作,IBM的技术利用各类数据资源,帮助打造了一种网络效应,罗玛解释说:“当你把所有事物汇集在一起时,你实际上就获得了最好的研发人员,而且能够让整个业界真正参与到这个帮助他人的事业中来。”(财富中文网)
译者:Feb
研发新冠疫苗的医疗研究人员和各大公司都在搜寻治疗新冠病毒的捷径,并在这一期间获得了来自于人工智能超级计算机的协助。
在疫情爆发伊始,IBM面向全球数百所大学、公司以及梅约诊所和克利夫兰诊所这类医疗机构部署了Watson人工智能。IBM Watson Health业务总经理保尔·罗玛在周二《财富》杂志举办的线上健康头脑风暴大会上称,他们“都在这个组装起来的超级计算机上进行试验,并获取发现。”
例如,梅约诊所正在研究采用恢复期血浆疗法(也就是采用从愈后新冠病毒患者身体中采集的抗体)来治疗新冠病毒,同时也在IBM的帮助下探索现有疗法治疗其他疾病的潜在疗效。
梅约诊所的总裁兼首席执行官吉安里克·法鲁吉亚在虚拟会议上说:“我们知道不能坐等疫苗的出现。我们必须携手IBM和其他合作伙伴,打造这个生态系统,并回收该系统中的旧药品。”
例如,法鲁吉亚提到了吉利德的试验药物瑞德西韦,这是第一个获美国食品与药品管理局新冠病毒治疗紧急授权的疗法。多年来,该药一直在围绕治疗埃博拉等其他病毒进行实验。法鲁吉亚称:“瑞德西韦并不是老药,但也不是新药。”
罗玛指出,IBM Watson的优势在于超级计算机加速研究过程的能力。他说:“以往在标准传统的计算环境中需要数周来建模和运行的事情基本上可以在几分钟之内完成。你可以在一天的时间内完成此前需要数月才能完成的建模和工作。”
通过与众多开发疫苗的机构合作,IBM的技术利用各类数据资源,帮助打造了一种网络效应,罗玛解释说:“当你把所有事物汇集在一起时,你实际上就获得了最好的研发人员,而且能够让整个业界真正参与到这个帮助他人的事业中来。”(财富中文网)
译者:Feb
As they search for a coronavirus vaccine, medical researchers and companies are looking for shortcuts to treat COVID-19—and they're getting an assist from artificially intelligent supercomputers.
At the beginning of the pandemic, IBM deployed its Watson A.I. technology around the world to hundreds of universities, companies, and medical organizations such as the Mayo Clinic and Cleveland Clinic. They "are all running experiments and creating findings from the supercomputers put together," Paul Roma, general manager for IBM Watson Health, said at Fortune's Brainstorm Health Virtual conference Tuesday.
While the Mayo Clinic, for one, is studying the use of convalescent plasma—blood antibodies from recovered coronavirus patients—to treat COVID-19, it's also looking at potential benefits of existing treatments for other diseases, with the help of IBM.
"We know we cannot simply wait for a vaccine," Gianrico Farrugia, the president and CEO of the Mayo Clinic, said at the virtual event. "We have to work with partners—IBM, others—to be able to create this ecosystem where we can recycle old drugs."
For example, Farrugia cited Gilead's experimental drug remdesivir, which was the first treatment to receive emergency authorization from the Food and Drug Administration for use on COVID-19 patients. That drug has been studied for years in trials targeting other viruses such as Ebola. "Remdesivir is not an old drug but it’s not a new one either," added Farrugia.
The advantage of IBM Watson, said Roma, is the supercomputers' ability to accelerate the research process. "What would have taken weeks to model and run in a standard and traditional computing environment can literally be done in minutes," he said. "You can get months’ worth of modeling and work done in the course of a day."
By partnering with so many institutions pursuing a vaccine, IBM's technology helps create a sort of network effect with the various data sources, Roma explained: "When you bring it all together, you can actually have the best researchers, you can have a community really engaged in helping people."